Bristol-Myers Squibb (BMY)
Salud · Farmacéuticas y biotecnología · USA
$62.47
+1.74%
Acerca de
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Fuente: Wikipedia · CC BY-SA 4.0
Sector
Healthcare
Sitio web
www.bms.comComparación con Índices
| Período | BMY | Dow Jones | Nasdaq | S&P 500 |
|---|---|---|---|---|
| 1D | +1.78% | -1.09%(+2.9) | -2.86%(+4.6) | -1.82%(+3.6) |
| 1W | +1.63% | -0.85%(+2.5) | -2.00%(+3.6) | -0.57%(+2.2) |
| 1M | +1.66% | +1.66%(+0.0) | -5.34%(+7.0) | -1.13%(+2.8) |
| YTD | +16.87% | +7.00%(+9.9) | +9.47%(+7.4) | +10.52%(+6.4) |
| 1Y | +35.62% | +8.85%(+26.8) | +7.22%(+28.4) | +10.82%(+24.8) |
Los números entre paréntesis muestran el rendimiento relativo vs el índice
Cierre anterior$61.39
Apertura$63.00
Rango del día$62.29 - $64.04
Rango 52 semanas$45.27 - $68.64
Volumen12.67M
Volumen prom.11.50M
Capitalización$128B
Beta (5A)0.18
Ratio P/E13.8x
BPA$4.51
Ratio P/B5.46x
Rendimiento dividendo4.03%
Ingresos$50B
Ganancia neta$9.2B
Margen operativo29.2%
Deuda total$45B
Efectivo$13B
Objetivo 1 año$65.25